Areas of expertise:

Prostate Cancer

Clinics:

• Thursday evening – Video or in person Nuffield Hospital (The Manor), Oxford

Member of:

• Royal College of Surgeons of Edinburgh (Fellow)
• British Association of Urological Surgeons (BAUS
• BAUS Section of Oncology
• European Association of Urology (EAU)
• Americal Urology Association (AUA)
• American Association of Cancer Research (AACR)

Contact details:

Online booking

Tel:01865-307733
email: admin@oxfordurologyassociates.uk

Subspecialty services that this consultant provides:

Alastair Lamb specialises in:-

• Discussion of PSA and advising regarding investigations
• Prostate diagnostics including interpretation of MRI, PSMA-PET
• Prostate biopsy (local anaesthetic transperinal biopsy, LATP)
• Surgical management of prostate cancer

Languages spoken:

• English
• Conversational French & Spanish

Current posts:

• Honorary Consultant Urological Surgeon, Guy’s and St Thomas’ NHS Foundation Trust;
• Cancer Research UK Advanced Clinician Scientist Fellow;
• Group Leader & Reader in Urology, Barts Cancer Institute, Queen Mary University of London

Profile

Born in Edinburgh, but growing up and schooled in South Oxfordshire, Alastair Lamb did initial medical training at Oxford (Corpus Christi College) and Edinburgh Universities, followed by registrar training as an ACF/ACL in Cambridge from 2007 – 2016. During this time, he did a PhD with Professor David Neal on the molecular genetics of prostate cancer at the CRUK Cambridge Institute. His specialty fellowship training took place Associate Professor Declan Murphy at Peter MacCallum Cancer Centre in Melbourne, Australia 2016-2017 before appointment by Professor Freddie Hamdy to an academic consultant post in Oxford in April 2017. He is now a Cancer Research UK funded clinician scientist & urologist based at Barts Cancer Institute and Guys Hospital in London.

Clinically, he manages patients across the full spectrum of localised prostate cancer from PSA counselling, through diagnosis, surveillance and robotic prostatectomy. He introduced LATP prostate biopsy to Oxford as well as a prostatectomy planning meeting to ensure robust discussion of all cases and a consensus approach to operative steps (https://youtu.be/p_XVH7DAFD8), on the basis that intentionality and teamwork matters in complex surgery.

Research

Alastair runs a scientific group called SPACE (Spatial Prostate Assessment and the Circulating Environment; https://www.nds.ox.ac.uk/research/prostate-biology/areas-of-research/spatial-clonal-biolog) whose main interest is the molecular basis of localised prostate cancer. His lab interrogate spatial clonal biology to unpack prostate cancer heterogeneity, with a focus on identifying and defining clonal lethality. The longer term objective is to change the paradigm of prostate cancer screening, diagnosis and treatment. The first part of this work was published in Nature in 2022 (www.nature.com/articles/s41586-022-05023-2; youtu.be/YdzF0-PFXhc) with a follow up analysis in Molecular Cancer in 2023 (molecular-cancer.biomedcentral.com/articles/10.1186/s12943-023-01863-2).

Alastair is also involved in clinical trials research, as co-Chief Investigator of the TRANSLATE Trial (https://translate.octru.ox.ac.uk/translate/welcome-to-the-translate-trial), and a local Investigator for the ELIPSE (https://w3.abdn.ac.uk/hsru/ELIPSE),  ATLANTA (www.imperialprostate.org/atlanta), PROMOTE (https://www.ndorms.ox.ac.uk/octru/trials-portfolio/trials-in-set-up/promote) and FINESSE Trials (https://www.finessetrial.org/). Alongside this he set up the QUANTUM Biobank at Oxford (https://www.nds.ox.ac.uk/quantum) to facilitate tissue collections complementing research into urological malignancies.